GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Arich Enterprise Co Ltd (ROCO:4173) » Definitions » 3-Year EBITDA Growth Rate

Arich Enterprise Co (ROCO:4173) 3-Year EBITDA Growth Rate : 7.90% (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Arich Enterprise Co 3-Year EBITDA Growth Rate?

Arich Enterprise Co's EBITDA per Share for the three months ended in Mar. 2024 was NT$0.42.

During the past 12 months, Arich Enterprise Co's average EBITDA Per Share Growth Rate was 8.50% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 7.90% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 1.30% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -0.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Arich Enterprise Co was 48.10% per year. The lowest was -33.60% per year. And the median was -10.70% per year.


Competitive Comparison of Arich Enterprise Co's 3-Year EBITDA Growth Rate

For the Pharmaceutical Retailers subindustry, Arich Enterprise Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arich Enterprise Co's 3-Year EBITDA Growth Rate Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Arich Enterprise Co's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Arich Enterprise Co's 3-Year EBITDA Growth Rate falls into.



Arich Enterprise Co 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Arich Enterprise Co  (ROCO:4173) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.


Arich Enterprise Co 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Arich Enterprise Co's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Arich Enterprise Co (ROCO:4173) Business Description

Traded in Other Exchanges
N/A
Address
No.880, Zhongzheng Road, 14F-5, Zhonghe District, Taipei, TWN, 235601
Arich Enterprise Co Ltd is a Taiwan-based company operating in the pharmaceutical industry. The company is engaged in providing medical sales and promotion and logistics services. The company markets and sells pharmaceutical products. The company's services cover customers including medical centers, area hospitals, district hospitals, general practitioner, and key accounts which includes chain stores and hyper markets, drug stores, and wholesalers. The product portfolio of the company includes Actos, Aftach, Cytotec, Gaster, Prometin, Hicee, Lederscon, Alinamin, Nacid tab, Setoral, Sibutil, and many more.

Arich Enterprise Co (ROCO:4173) Headlines

No Headlines